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The previously described cqclic delta opioid receptor-selective tetrapeptide H-Tyr-D-C$s-Phe-D-Pkn-OH 
(JOM-13) was modified at residue 3 by incorporation of both natural and unnatural amino acids with varying 
steric, electronic, and lipophilic properties. Effects on mu and delta opioid receptor binding affinities were 
evaluated by testing the compounds for displacement of radiolabeled receptor-selective ligands in a guinea 
pig brain receptor binding assa). Results obtained with the bulky aromatic 1-Na13 and 2-Na13 substitutions 
suggest that the shape of the receptor subsite with which the side chain of the internal aromatic residue in- 
teracts differs for delta and m u  receptors. This subsite of either receptor can accommodate the transverse steric 
bulk of the 1-NaI3 side chain but only the delta receptor can readily accept the more elongated 2-Na13 side 
chain. Several analogs with pi-excessive heteroaromatic side chains in residue 3 were examined. In general, 
these analogs display diminished binding to mu and delta receptors, consistent with previous findings for 
analogs with residue 3 substitutions of modified electronic character. Several analogs with alkyl side chains 
in residue 3 were also examined. While delta receptor binding affinity is severely diminished with Val3, Ile3, 
and Leu3 substitutions. Cha3 substitution is very well tolerated, indicating that, contrary to the widely held 
belief, an aromatic side chain in this portion of the ligand is not required for delta receptor binding. Where 
possible, comparison of results in this delta-selective tetrapeptide series with those reported for analogous 
modification in the cyclic delta-selective pentapeptide [ D - P d ,  ~-Pen’]enkephaIin (DPDPE) and linear 
pentapeptide enkephalins reveals similar trends. 
Ke!, n’ord.s: aromatic side chain; conformational restriction: delta opioid receptor; deltorphin analog; dermorphin analog; 
disulfide bond; enkephalin analog: hcteratom: mu opioid rcceptor; opioids 
The heterogeneity of opioid receptors is well-established 
and the existence of a least three opioid receptor types, 
designated mu, delta and kappa, is widely accepted. In 
recent years, a body of evidence has accumulated which 
indicates that the mu and delta receptor types differ in 
their structural and conformational requirements for 
peptide ligand binding (1, 2) and may mediate different 
pharmacological and physiological events (3). Confor- 
mational restriction of enkephalin analogs has proven 
a valuable means for assessing disparities between the 
Abbreviations recommended by ILJPAC-IUD Commisaion on Bio- 
chemical Nomenclature have been used. Other abbreviations: .4CN. 
acetonitrile; Boc, t-hutqlosycarbonyl; COSY. correlation spectro- 
scopy: DAMGO, [D-AI~’ .  NMePhe’. GI?’-ollenkephalin: DCC. di- 
cyclohexylcarbodiimide: DMF. dimethylforniamide; DPDPE. [ D- 
Pen?, u-Pen’]enkcphaiIn; DPM. disintegrations per minutc: FAB- 
MS, Cast atom bombardment-mass hpectrometr); H0.4~. acetic acid: 
HOBt, I-h).drox!benzotriazole: NMR, nuclear magnetic resonance; 
NOE. nuclear Owrhau\er effcct. NOESY. nuclc:it- O\ erhxtser effect 
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spcctroscopy: RP-HPLC. reverse phase-high performance liquid 
chromatography; TFA. trifluoroacetic acid; TLC, thin-layer chroma- 
tography; TSP. (trir:irthylsilyl)propiunic acid; Tris. tris[hydroxyl- 
meth~l]aminoniethanc; U69.593,5r.7r3 804 - ) -N-[  7-( 1-pyrrolidinyl). 
l-osaspiro(~,5)dec-8-yl]benrcneacetamide. Unusual amino acids: 
Cha. ?-(c!clohex).l)alaninc; 1-Nal, 3-( I-naph1hyl)alanine; 2-Nal. 3- 
(2-naphth!l)alanine: Pal, 3-(3-p).ridq.l)alaiiinc; Pen, peniciilaniine; 
Thi. 3-(’-thiun)l)alanine. 
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tion and cleavage from the resin were accomplished by 
treatment with anhydrous hydrogen fluoride in the pres- 
ence of 57; p-cresol and 5 %  p-thiocresol (10) for 
45 min at 0 O . Prior to cyclization, linear peptides were 
purified by reverse phase-high performance liquid chro- 
matography (RP-HPLC) on a Vydac 218TP C-18 col- 
umn (2.5 x 22 cm) using the solvent system 0.1 q,,, TFA 
in water/O.l% TFA in acetonitrile, by a gradient of 
10-500,; organic component in 40 min. Cyclization to 
disulfide analogs was accomplished by treatment of an 
aqueous solution (pH 8.5) of the linear free sulfhydryl- 
containing species with K3Fe(CN)6 for ca. 1 h. Cy- 
clized peptides were then purified by RP-HPLC as de- 
scribed above, and pure fractions were lyophilized. 
peptide binding characteristics at each of the opioid 
receptor types, since peptide analogs designed with ap- 
propriate conformational constraints may possess the 
ability to adopt the conformation required for interac- 
tion at one receptor type but not another. We have 
previously described (4) a series of disulfide-containing 
tetrapeptides (des-Gly3 enkephalin analogs) which 
can be viewed as truncated, cyclic analogs of the frog 
skin derived heptapeptides, dermorphin (5) and deltor- 
phin (6, 7). The lead compound in this series, Tyr-D- 
Cys-Phe-D-PenOH (JOM- 13), exhibits considerable 
delta receptor selectivity and a higher delta binding 
affinity than the standard delta selective ligand, [D- 
Pen', ~-Pen~]enkephalin (DPDPE (8)) (4). In addi- 
tion, JOM-13 and its analogs possess a greater degree 
of structural rigidity than DPDPE due to the absence 
of the central glycine residue found in the pentapeptide 
and might therefore prove to be even more amenable to 
conformational analysis than DPD.PE. In an effort to 
further investigate this tetrapeptide series, to allow com- 
parison with some of the cyclic disulfide-containing 
pentapeptide enkephalin analogs, and to explore the 
possibility that the Phe3 residue of dermorphin/ 
deltorphin-like tetrapeptides and the Phe4 residue of 
enkephalin-like pentapeptides interact differently at mu 
and/or delta opioid receptors (9), we have prepared 
several analogs of JOM- 13 with modifications designed 
to assess the effect of substitution of amino acids with 
varying steric, electronic, and lipophilic properties at 
each residue. These alterations of the cyclic parent te- 
trapeptide, particularly at the aromatic Phe residue, 
provide interesting insights into binding requirements 
of this series to the mu and delta opioid receptors. Both 
the Tyr' and Phe4 (or Phe3) aromatic side chains are 
believed to play a critical role in the enkephalin bind- 
ing conformation, each residue interacting at the recep- 
tor (2). Analogs described here were designed to probe 
the steric, electronic, and lipophilic requirements of the 
residue 3 side chain aromatic function by replacement 
of the Phe3 residue of JOM-13 with larger aromatic 
groups, with heteroatomic aromatic side chains, or with 
nonaromatic aliphatic moieties. 
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Tyr-D-Cvsil-Nal)-D-PenOH (1). The title peptide was 
prepared as described for JOM-13 (4) using Boc-3-(1- 
naphthy1)-L-alanine (1-Nal) in place of Boc-Phe in the 
solid phase synthesis protocol. A 1.3 g sample of the 
protected, resin-bound peptide was treated with 12 mL 
HF, 0.6 g cresol, and 0.6 g p-thiocresol. After extrac- 
tion into 9: 1 DMF/80% HOAc and dilution with 01 u; 
TFA in H20, the disulfhydryl peptide was subjected to 
semipreparative HPLC, which yielded, after lyophiliza- 
tion, 113 mg of pure linear peptide. A sample of 43.0 mg 
of this peptide was oxidized as described above, yicld- 
ing after RP-HPLC, 20.1 mg of the title disulfide- 
containing peptide. 
Tyr-~-Cys-(2-Nal)-~-PenOH (2). The title peptide was 
prepared as described for JOM-13 (4) by substituting 
Boc-3-(2-naphthyl)-~-alanine (2-Nal) for Boc-Phe. A 
1.3 g sample of the protected, resin-bound peptide was 
treated with 11 mL HF, 0.6 g p-cresol, and 0.6 g p- 
thiocresol. After extraction into 9: 1 DMF/8O0/, HOAc 
and dilution with O.lp/, TFA in H'O, the disulfhydryl 
peptide was subjected to semipreparative HPLC, which 
yielded, after lyophilization, 79.5 mg of pure linear pep- 
tide. A sample of 43.0 mg of this peptide was subjected 
to oxidation as described above, yielding after RP- 
HPLC, 14.5 mg of the disulfide-containing peptide. 
METHODS 
Peptides 
Peptides were synthesized by standard solid phase 
methods similar to those previously described for the 
synthesis of JOM-13 (4), using chloromethylated poly- 
styrene (Merrifield) resin crosslinked with 1 "/, divinyl- 
benzene. Trifluoroacetic acid (TFA) was used for de- 
protection, and dicyclohexylcarbodiimide (DCC) and 
1 -hydroxybenzotriazole (HOBt) were employed to fa- 
cilitate coupling. Alpha-amino functions were t- 
butyloxycarbonyl (Boc) protected, and p-methylbenzyl 
protection was employed for the labile side chain sulf- 
hydryl groups of Cys and Pen. Simultaneous deprotec- 
Tvr-D-C.h-Thi-D-PhOH (3a and 36). The title peptide 
was prepared as described for JOM-13 (4) using Boc- 
3-(2-thienyl)-D,~-alanine (Thi) in place of Boc-Phe. A 
1.1 g sample of the protected, resin-bound precursor 
peptide was treated with 10 mL HF, 0.6 g p-cresol, and 
0.6 g p-thiocresol. After extraction into 9: 1 DMF/80"/, 
HOAc and dilution with 0.17; TFA in H20, the di- 
sulfhydryl peptide was subjected to semipreparative 
HPLC, which yielded, after lyophilization, 2 pools of 
impure diastereomeric peptide, each greatly enriched in 
one component, with masses of 26.7 mg and 45.9 mg, 
respectively. In each case. the entire sample was sub- 
jected to oxidation as described above. The earlier- 
eluting disulfhydryl peptide yielded, after oxidation and 
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RP-HPLC, 11.4 mg of cyclized peptide 3a. The later- 
eluting linear peptide yielded, after oxidation and puri- 
fication 7.2 mg of disulfide-containing peptide 3b. 
Tyr-o-Cis-Trp-o-PhOH (4). The peptide was prepared 
as described for JOM-13 (4) using Boc-L-tryptophan 
(Trp) in place of Boc-Phe. It should be noted that no  
indole-N protection was employed for this residue. In- 
stead, anisole was used as a cation scavenger in the 
TFA deprotection solution, to protect Nl1'-aIkylation. A 
1.2 g sample of the protected, resin-bound precursor 
peptide was treated with 11 mL HF, 0.6 g p-cresol, and 
0.6 g p-thiocresol. After extraction into 9: 1 DMF/80°, 
HOAc and dilution with 0.1 ?, TFA in H-0,  the di- 
sulfhydryl peptide was subjected to semipreparative 
HPLC, which yielded, after lyophilization, 115 mg of 
pure linear peptide. A sample of 49.5 mg of this peptide 
was subjected to oxidation as described above, yield- 
ing after RP-HPLC, 25.0 mg of the disulfide-containing 
peptide. 
m Tyr-D-Cys-His-D-PenOH (5J. The title peptide n as pre- 
pared as described for JOM- 13 (4) using Boc-N"-tosyl- 
L-histidine (His). Since it IS sufficiently acidic to cleave 
the tosyl protecting group, HOBt was eliminated from 
every coupling. A 1.5 g sample of the protected, resin- 
bound precursor peptide was treated with 13 mL HF, 
0.7 g p-cresol, and 0.7 g p-thiocresol. After extraction 
into 9:l DMF/80yo HOAc and dilution with O.lo0 
TFA in HzO, the disulfhydryl peptide was subjected to 
semipreparative HPLC, as described above; however, 
due to the high polarity of the His3 substituted peptide 
and the large sample volume, only partial purification 
was effected. Following lyophilization, the crude mate- 
rial was subjected to further isocratic RP-HPLC puri- 
fication at 8 % organic component, and 38.0 mg of pure 
linear peptide was obtained. This entire sample was 
subjected to oxidation as described above, yielding after 
extensive RP-HPLC (standard conditions, followed by 
isocratic conditions at 14;, organic component on a 
1 .O cm x 25 cm column), 5.5 mg of the desired disulfide- 
containing peptide. 
Tyr-D-Cbs-Pal-D-PkJH (4). The peptide was prepared 
as described for JOM-13 (4) using Boc-3-(3-pyridyl)- 
L-alanine (Pal) in place of Boc-Phe. A 1.1 g sample of 
the protected, resin-bound precursor peptide was 
treated with 10 mL HF, 0.5 g p-cresol, and 0.5 g p -  
thiocresol. After extraction into 9: 1 DMF/8070 HOAc 
and dilution with 0.1 o,, TFA in  HrO, the disulfhydryl 
peptide was subjected to semipreparative HPLC, which 
yielded, after lyophilization, 99.6 mg of pure linear pep- 
tide. A sample of 42.0 mg of this peptide was subjected 
to oxidation as described above, yielding after RP- 
HPLC, 14.5 mg of the disulfide-containing peptide. 
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Ti,r-D-C!,s-Cha-D-Pe?zOH (7). The title peptide was pre- 
pared as described for JOM-13 (4) employing Boc-3- 
(cyclohexy1)-L-alanine (Cha). A 1.3 g sample of the pro- 
tected, resin-bound precursor peptide was treated with 
12 mL HF, 0.6 g p-cresol, and 0.6 g p-thiocresol, and 
after extraction into 9: 1 DMF/80:/, HOAc and dilution 
with 0.1 To  TFA in H20, the disulfhydryl peptide was 
subjected to semipreparative HPLC. This yielded, after 
lyophilization, 67.5 mg of pure linear peptide. A sam- 
ple of 41.8 mg of this peptide was subjected to oxida- 
tion as described above, yielding after RP-HPLC, 
23.0 mg of the target disulfide-containing peptide. 
Ti9r-D-ci!s- Vaf-D-PenOH (8). The title peptide was pre- 
pared as described for JOM- 13 (4) by substituting Boc- 
L-valine (Val) for Boc-Phe. A 1.3 g sample of the pro- 
tected, resin-bound peptide was treated with 11 mL 
HF, 0.6 g p-cresol, and 0.6 g p-thiocresol. After extrac- 
tion into 9:l DMF/8O0, HOAc and dilution with 0.1 % 
TFA in H10, the disulfhydryl peptide was subjected to 
semipreparative HPLC, which yielded, after lyophiliza- 
tion, 89.0 mg of linear peptide. A sample of 39.0 mg of 
this peptide was subjected to oxidation as described 
above, yielding after RP-HPLC, 6.5 mg of the target 
disulfide-containing peptide. 
T,ir-D-c~,s-Leu-D-P~noH (9). The title peptide was pre- 
pared as described for JOM-13 (4) by substituting Boc- 
L-leucine (Leu) for Boc-Phe. A 1.1 g sample of the 
protected, resin-bound peptide was treated with 10 mL 
HF, 0.5 g p-cresol, and 0.5 g y-thiocresol. After extrac- 
tion into 9: 1 DMF/80"& HOAc and dilution with 0.1 yo 
TFA in HzO, the disulfhydryl peptide was subjected to 
semipreparative HPLC, which yielded, after lyophiliza- 
tion, 125 nig of linear peptide. A sample of 32.0 mg of 
this peptide was subjected to oxidation as described 
above, yielding after RP-HPLC, 16.8 mg of the target 
di sulfide-con t aining peptide. 
T~r-D-C~s-Ile-D-PenOH (10). The title peptide was pre- 
pared as described for JOM-13 (4) by substituting Boc- 
L-isoleucine (Ilc) for Boc-Phe. A 1.1 g sample of the 
protected, resin-bound peptide was treated with 10 mL 
HF, 0.5 g p-cresol, and 0.5 g p-thiocresol. After extrac- 
tion into 9: 1 DMFj80 ?o HOAc and dilution with 0.1 ; 
TFA in H20, the disulfhydryl peptide was subjected to 
semipreparative HPLC. which yielded, after lyophiliza- 
tion, 42.5 mg of pure linear peptide. A sample of 20.5 mg 
of this peptide was subjected to oxidation as described 
abovc, yielding aftcr RP-HPLC, 5.0 mg of the target 
disulfide-containing peptide. 
Peptide anulJxis 
Final product purity was assessed by analytical RP- 
HPLC on a Vydac C- 18 column (4.6 min x 250 mm) by 
a gradient of 10-70"/', organic component over 30 rnin. 
452 
Opioid receptor binding 
Receptor binding assays 
Binding assays were based on the displacement by the 
test compounds of radiolabeled (['HI) [ D-Ala', NMe- 
Phe', Gly5-ollenkephalin (DAMGO) (mu ligand), 
DPDPE (delta ligand), and U69,593 (kappa ligand) (all 
from Amersham) from opioid receptors in guinea pig 
brain membrane receptors. For the membrane prepa- 
rations, 10 frozen guinea pig brains (Pel-Freez Biolog- 
icals), weighing approximately 36 g, were thawed at 5 O 
for 3 h. The brains were then suspended in cold 50 mM 
Tris buffer, pH 7.4, at a concentration of 0.1 g/mL 
(approximately 360 mL total) and homogenized for 20 s 
on a Brinkman Polytron Homogenizer (model # P T  
10-35, probe model # PT 20 ST) at one-half maximum 
speed. The homogenate was centrifuged for 15 min at 
14000 x g at 4", and the supernatant was discarded. 
The pellets were resuspended in 360 mL cold 50 mM 
Tris buffer by homogenization for 20 s at one-quarter 
maximum speed. Centrifugation at 4" was repeated at 
14000 x g  for 15 min, and the supernatant was again 
discarded. The pellets were again resuspended by ho- 
mogenization (20 s at one-quarter speed) in 360 mL 
50 mM Tris buffer at 25 O ,  pH 7.4. After incubation at 
37" for 30 min to release endogenous opioids, the ho- 
mogenate was centrifuged at 14000 x g  for 15 min at 
4". Pellets of brain membrane finally were resuspended 
in 400mL 50mM Tris buffer on ice, pH 7.4, by ho- 
mogenization for 20 s at one-quarter speed. The mem- 
brane suspension was divided into aliquots of the ap- 
propriate size for a set of binding assays (approximately 
10 mL) and stored in capped plastic test tubes at -80'. 
Before use in a binding assay, each aliquot was thawed, 
homogenized (8 strokes in a glass homogenizer with a 
Teflon pestle), and stored on ice. 
Receptor binding assays, done in triplicate, were per- 
formed as follows: In polypropylene tubes in an ice 
bath, assay components were carefully pipetted in the 
following order: 25 pL water (total binding), displacing 
ligand in water (nonspecific binding), or test compound 
(varying concentrations prepared by serial dilutions) in 
water; then, 200 pL membrane preparation (determined 
in control experiments to be in the linear range of the 
specific binding vs. protein concentration dependence). 
These were gently vortexed and preincubated in a tem- 
perature regulated water bath for 15 rnin at 25 O, then 
placed on ice for the addition of 25 pL of the radioli- 
gand solution in 50 mM Tris buffer (pH 7.4). The assay 
suspension in each tube was again gently vortexed 
and incubated in a water bath to reach equilibrium 
(75 rnin for assays using 0.6 nM ["IDAMGO and 
1.8 nM ['HIDPDPE, 90 rnin for assays using 0.9 nM 
[ 3H]U69,593, each determined from time dependence 
studies of specific binding) at 25 O . Before harvesting 
the samples, the filter paper sheet was pretreated for 
1 rnin with amyl alcohol-saturated water, followed by 
one Tris buffer wash. Subsequently, the samples were 
diluted, rapidly filtered, and washed twice with 4 mL 
cold Tris buffer (pH 7.4), using a 24-tube Brandel Cell 
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with a flow rate of 1 mL/min. Peaks were monitored at 
230 nm and 280 nm and analyzed with Waters Maxima 
820 software. Peptide purity was > 95 9" in each case. 
All analytical RP-HPLC gradients were run using the 
solvent system 0.1% TFA in water/O.l"/, TFA in 
acetonitrile. Peaks which also appeared in chromato- 
grams in which no peptide was injected were consid- 
ered to be artifacts and were ignored. Peptide purity 
was then assessed by peak integration. In addition, all 
newly reported peptides were subjected to thin-layer 
chromatography (TLC) on precoated silica gel plates in 
three solvent systems: (solvent ratios are vo1ume:vol- 
ume) (A) ti-butano1:acetic acid:water (4: 1:5, organic 
component only); (B) n-butanokwater (containing 3.5 yo 
acetic acid and 1.5 7 ,  pyridine) (1 : 1,organic component 
only); (C) n-amyl alcoho1:pyridine:water (7:7:6). Three 
methods of visualization (ninhydrin, ultraviolet absorp- 
tion, iodine vapor) detected a single spot after TLC in 
each solvent system. 
To assure that the final peptides had been success- 
fully cyclized, the presence of free sulfhydryl groups 
in final product peptides was assessed by testing 
with 5,5 '-dithiobis(2-nitrobenzoic acid) (Ellman's re- 
agent). When combined with free sulfhydryl-containing 
species, this reagent forms an adduct giving a charac- 
teristic yellow color and absorbance at 412 nm (1 1). 
In all cases, absorbances of the final peptides at this 
wavelength were indistinguishable from sulfhydryl-free 
controls confirming the absence of free sulfhydryl 
groups. 
'H NMR spectra, recorded on General Electric GN- 
500 and IBM WP 270 SY spectrometers, operating at 
500 MHz and 270 MHz, respectively, were used ana- 
lytically for structure confirmation of the final peptides. 
Samples contained 1-2 mg of the compound in D20, 
acidified D20 or DMSO solvent, with 2,2,3,3- 
tetradeuterio-3-(trimethylsilyl)propionic acid, sodium 
salt (TSP-d4) added as the internal standard. Diagnos- 
tic resonances arising from the methyl groups and the 
alpha proton of penicillamine and the aromatic reso- 
nances of tyrosine confirmed the presence of these res- 
idues. No resonances were observed that could not 
be accounted for, and all resonances pertaining to 
specifically-modified residue 3 amino acids were present 
(peak patterns consistent with appropriate aromatic 
and nonaromatic residues). Some analogs were sub- 
jected to 2D COSY analysis to establish intraresidue 
connectivities and/or to 2D NOESY experiments to 
obtain primary sequences from intraresidue NOE in- 
teractions. In each case, the anticipated sequence was 
confirmed. All peptides displayed NH-aCH-fiCH2 con- 
nectivities consistent with the presence of cysteine (half 
cystine). 
Final products were subjected to fast atom 
bombardment-mass spectrometry (FAB-MS) to deter- 
mine product molecular weights. In all cases the 
appropriate, predicted molecular weights were con- 
firmed. 
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Harvester (model M-24R). Filter discs were removed 
with forceps and placed in scintillation vials, to which 
1 mL ethanol and 10 mL Scintiverse liquid scintillant 
were added. Capped vials were shaken by hand for 10 s 
and allowed to sit several hours. Radioactivity on the 
filters was then determined by liquid scintillation count- 
ing for 10 min per sample. Radioligand stock solution 
aliquots also were counted similarly after transfer into 
vials and addition of 10 niL Scintiverse. Inhibition of 
radiolabeled ligand binding by the test compounds was 
computed from maximal specific binding, determined 
with an appropriate excess of unlabeled ligand (10 PM 
DPDPE or U69,593; 5 /AM DAMGO). At the concen- 
trations employed for the assays, total binding of each 
radioligand to the membrane preparation typically 
measured N 2000 DPM, while nonspecific binding 
was approximately 200 DPM for [3H]DAMG0 and 
[3H]U69,593 and 400 DPM for [3H]DPDPE. I C ~ O  
values were obtained by linear regression from plots 
relating inhibition of specific binding to the log of 12 
different ligand concentrations, using the computer pro- 
grams LIGAND (12) (Biosoft Software). K, values 
were similarly calculated using values for KD of each 
ligand, determined by analysis of saturation binding 
experiments. Values of KD so determined were: [ 3H]D- 
For binding to kappa receptors, expected to be weak 
for all analogs, the protocol was altered to include only 
5 ligand concentrations (in duplicate). Analysis by 
PDPE, KD = 2.97 nM; ['HIDAMGO, KD = 0.85 nM. 
LIGAND. using K D  = 0.9 nM for [?HH]U69,593, yielded 
estimates or lower limits for Ki. 
RESULTS AND DISCUSSION 
The following modified and naturally occurring amino 
acids were incorporated as residue 3 substitutions in 
the lead tetrapeptide, Tyr-D-Cys-Phe-D-PehoH (JOM- 
13): 3-( 1-naphthy1)-L-alanine (1-Nal) (l), 3-(2- 
naphthy1)-L-alanine (2-Nal) (2), 3-(2-thienyl)-~.L- 
alanine (Thi) (3a and 3b), L-tryptophan (Trp) (4), L- 
histidine (His) (S), 3-(3-pyridyl)-~-alanine (Pal) (6). 3- 
(cyclohexy1)-L-alanine (Cha) (7), L-valine (Val) (S), L- 
leucine (Leu) (9), and L-isoleucine (Ile) (10). Each of 
these modifications was designed to test the influences 
of varying steric and electronic character and lipophilic- 
ity in this region of the peptide molecule; we have re- 
ported previously (13) that each of these determinants 
appears to play an important role in interaction with the 
opioid binding sites. Receptor binding affinities for mu, 
delta, and kappa opioid receptors, as measured by Ki 
values ( k  standard crrors of the mean) against 
[ 3H]DAMG0, [ 3H]DPDPE, and [ 3H]U69,593, re- 
spectively, for these peptides are provided in Table 1 as 
are comparable data for DPDPE and the parent tet- 
rapeptide, JOM-13. As can be seen from Table 1, Ki 
values for kappa binding for all peptides reported here 
indicate low affinity for the kappa receptor site. Values 
m 
TABLE 1 
Opioid rerepplor biriding profiles ?f r?.clic rerrqeprides 
Peptide Analog No Binding K ,  ( n M )  KSPc)/ 
Kd8) 
DAMGO DPDPE U69.593 
Tyr-D-Pdn-Gly-Phe-D-P:nOH (DPDPE)  810 k 66 3.98 2 0.46 > 10000 204 
Tyr-D-C;s-Phe-PhOH (JOM-13) I07 2 1.0 1.79 2 0.1 1 > 10000 60 
Tyr-D-Cis-( I-Nal)-D-PknOH 1 91 .526 .5  2.85 k 0.33 - 1500 32. I 
Tyr-~-C;s-(2-Nal)-D-PknOH 2 590 k 90 7.23 2 0.20 - 3 000 265 
Tyr-D-C~s-Thi-D-PknOH 3a 1880 2 608 65.3 2 7.2 > 10000 28.8 






4 1 8 3 i  19 2.49 2 0.1 1 - 600 73.5 
5 10700 2 860 56.3 4.5 > 10000 200 
6 1610 5 350 1 3 2 2  17 > 10000 12.2 
8 7400 f 1 180 827 2 85 > 10000 8.95 
9 413544 1 8 8 k 4 4  z 10000 2 20 
10 543 70 3 5 0 2 4 1  > 10000 1.55 
DAMGO = ['HI[ D-Ala', NMePhe', Glq5--ol]enkephaIin 
DPDPE = [ 'H l [~-Pen ' .  D-Pen5]enkephaliii 
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other hand, retains similar delta activity but displays a 
five fold reduction in affinity at the mu receptor; con- 
sequently, the delta selectivity of this analog is enhanced 
ca. fourfold relative to JOM-13 and, in fact, 2 displays 
increased delta receptor selectivity and affinity relative 
to DPDPE. The similar delta binding affinities of both 
naphthylalanines, each comparable to that observed for 
JOM-13, suggest that the delta receptor binding pocket 
for this element of the pharmacophore is both “broad” 
and “deep” and can thus tolerate rather bulky, flat 
aromatic side chains at this position. By contrast, the 
reduced mu binding affinity of 2 compared with 1 sug- 
gests that this receptor binding subsite is broad but 
not deep. The mu receptor results observed here are 
consistent with previous observations in cyclic, mu 
receptor selective tetrapeptides as well as in pentapep- 
tide enkephalin analogs. In the former case, Schiller 
has observed in his mu selective series of structure: 
were typically > 10000 nM and in all cases reflected 
substantially weaker binding than at either mu or delta 
sites. Also presented in Table 1 is the ratio of the mu 
and delta Ki values for each compound, which provides 
a measure of the delta (vs. mu) selectivity of the com- 
pound. Physicochemical data for newly reported pep- 
tides are presented in Table 2. 
Compounds 1-6 were designed to assess the effects 
of altered size, lipophilicity, and electronic character of 
the residue 3 side chain, while maintaining aromaticity. 
The naphthylalanine-containing analogs 1 and 2 differ 
in the point of side chain attachment of the aromatic 
naphthyl system to the fl-carbon and, therefore, differ 
in the orientation of the aromatic function. Replace- 
ment of the Phe phenyl ring with a naphthyl moiety 
increases the steric bulk and lipophilicity at this crucial 
residue, as reflected by relatively late RP-HPLC elution 
times. Further, the pharmacological consequences of 
the differing orientation of the aromatic naphthyl moi- 
ety relative to the backbone allow the nature of the 
receptor subsite with which the residue 3 side chain 
interacts to be probed. When compared to JOM-13, 1, 
containing 1-Nal, is essentially equiactive at the mu 
receptor while suffering only a minor loss of affinity at 
the delta type. The 2-Nal-containing analog, 2, on the 
Tyr-D-Oh-X-GiuNHz, that The l-Na13 analog displays 
comparable mu receptor affinity relative to Tyr-D- 
Om-Phe-GluNH2, while the 2-Na13 compound exhib- 
its a reduction in mu binding affinity (14). For pen- 
tapeptide enkephalins, it has been reported that in linear 
enkephalinamide analogs the 2-Na14 substitution, com- 
 
TABLE 2 
Phjiriocheniical dam for yclic tetrapeptides 
Peptide Analog No. HPLC Purity [OIYield TLCRf FAB-MS 
(%Y (“b)* Mol wt 
I” I I b  A B C - 
Tyr-D-Cys-( 1 -Nal)-D-PenOH 1 17 35 100 47 0.70 0.62 0.66 610 
Tyr-D-C~s-(2-Nal)-D-PknOH 2 17 36 100 34 0.71 0.71 0.73 610 
Tyr-D-C3s-Thi-D-P(enOH 3a 16 31 96 43 0.54 0.39 0.59 566 
Tyr-D-Cis-Thi-D-PLnOH 3b 14 29 98 16 0.56 0.49 0.62 566 
Tyr-D-Cis-Trp-D-P-knOH 4 16 31 99 50 0.61 0.59 0.67 599 
Tyr-D-Cis-H js-D-PknOH 5 12 25 98 15 0.02 0.02 0.18 550 
Tyr-D-Cis-Pal-D-PknOH 6 12 26 99 35 0.23 0.18 0.67 56 1 
Tyr-D-C~s-Cha-D-PknOH 7 16 32 100 55 0.78 0.76 0.79 566 
Tyr-D-C~s-Val-D-PknOH 8 13 26 96 17 0.41 0.35 0.64 5 12 
Tyr-D-Cys-Leu-D-PenOH 9 14 28 99 53 0.68 0.51 0.69 526 
Tyr-D-Cys-lie-D- PenOH 10 13 27 99 25 0.69 0.52 0.70 526 
m 
m 
HPLC elution on a Vydac 218TP C-18 column (0.46 cm x 25 cm) using a linear gradient of 10-70y0 organic component in 30 min at a 
flow rate of 1 ml jmin .  Solvent system was 0.10,; (w/v) TFA in w,ater/O. 1 :; (wiv) TFA in acetonitrile. The solvent front (“brcakthrough peak”) 
eluted at 3.0 min. 
HPLC elution time on a Vydac 218TP C-18 column (0.46 cm x 25 cm) using a linear gradient of 0-70:, organic component in  70 min 
at a flow rate of 1 mL/min. Solvent system was 0. lo; (w/v) TFA in water/O. I :(, (w/v) TFA in acetonitrile. The solvent front (“breakthrough 
peak”) eluted at 3.0 min. 
L. Purity of final cyclized peptide as assessed by HPLC peak integration from chromatogranis at 230 nm. 
Yield in peptide cyclization/oxidation reaction, after purification. 
Rf values for thin-layer chromatograms in solvent systems: (A) n-butano1:acetic acid:water (4: 15, organic component only); ( B )  n- 
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butano1:water (containing 3.57; acetic acid and 1.594 pyridine) ( l : l ,  organic component only); (C) n-amyl a1cohol:pyridine:water (7:7:6). 
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pared with 1-Nal-' substitution, results in a 10-fold po- 
tency drop in the guinea pig ileum (GPI) bioassay (1 5), 
a prototypical mu receptor assay (16). 
In analogs 3a, 3b, 4, 5, and 6 the electronic and 
lipophilic character of the residue 3 side chain was 
modified considerably by the incorporation of various 
heteroaromatic moieties. For analog 5, the possible 
partial positive charge (at physiological pH and under 
assay conditions at pH 7.4) on the 5-membered imida- 
zole ring of the His3 side chain makes it quite polar, and 
this hydrophilic analog elutes earliest on RP-HPLC of 
all members of the series (although, it should be kept 
in mind that under the acidic conditions of RP-HPLC, 
the charged nature of this residue is more evident than 
in the binding assay). Most likely as a consequence of 
this hydrophilicity, the mu and delta receptor binding 
affinities of analog 5 are reduced 100-fold and 30-fold, 
respectively. Similarly, compound 6,  which contains 
Pal, is very hydrophilic. The pK, for the Pal side chain, 
however, is approximately 5.3 (16). so the positively 
charged form should be virtually unpopulated under 
assay conditions. Nonetheless, its delta binding is com- 
promised 74-fold relative to JOM-13, and a 15-fold 
reduction in mu affinity is observed. As a result, this 
modification proves to be even more detrimental than 
His3 substitution for delta receptor interaction, though 
mu binding is better for the Pal3 analog. Compounds 
3a, 3b, and 4 display intermediate lipophilic character 
when compared to other tetrapeptides in the series. 
Each of these aromatic modifications in fairly well- 
accommodated in this tetrapeptide series. Compound 
3a probably contains the D-Thi amino acid, which 
would account for its lower binding affinity than the 
diastereomeric peptide, 3b, which displays only a slight 
to moderate reduction in opioid binding ( 1  S-fold re- 
duction at the mu type and fivefold reduction at the 
delta receptor). Trp proves an even better substitution 
at residue 3 in this series, as analog 4 retains similar 
delta affinity to the lead compound and suffers only a 
slight decline in mu binding. A similar benign effect of 
Trp4 for Phe4 substitution in linear pentapeptide en- 
kephalins has been reported. One further point pertain- 
ing to this particular group of analogs should be noted. 
The electronic character of the 5-membered heterocy- 
clic aromatic systems for compounds 3a, 3b. and 5 
should be expected to be pi-excessive. The resultant 
decline in delta binding affinity would be consistent 
with results of affinity reduction observed upon substi- 
tution on the Phe aromatic ring with electron releasing 
groups and the corresponding affinity enhancement as- 
sociated with electron withdrawing substituents ( 13). 
Data for analog 6 ,  however, tend to contradict this 
analogy, since the 6-membered pi system of the Pal 
heterocycle should be electron deficient, and this ana- 
log displays less delta binding affinity than the afore- 
mentioned electron-rich analogs. This poor binding in 
general may be attributed to the hydrophilicity of the 
residue 3 side chain, consistent with the simultaneous 
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requirement for lipophilicity in the Phe3 substituted ar- 
omatic analogs (1 3). 
Previous studies in the linear enkephalins have led to 
the proposal that the Phe aromatic ring is required for 
delta, but not mu, interaction (18); in fact, saturation of 
the phenyl ring resulting in Cha, a bulky and lipophilic 
side chain substituent, is well tolerated at the mu re- 
ceptor (19). Compound 7 and the less bulky alkyl side 
chain-containing analogs 8,9 ,  and 10 were designed to 
examine this tendency in the cyclic tetrapeptide series. 
The Val3 analog, 8, exhibits a drastic reduction in bind- 
ing affinity at both receptor types, 69-fold at the mu 
receptor and 462-fold at the delta type, relative to JOM- 
13. For the Leu3 substitution in this series, both li- 
pophilicity and side chain length of the non-aromatic 
residue are increased beyond those of Val. As a result, 
compound 9 apparently can achieve a greater binding 
interaction at both m and delta opioid sites. However, 
binding affinities at both receptor types are still reduced 
relative to JOM-13, by a rather modest factor of 4 at 
mu and a more significant factor of 105 at delta sites. 
Similarly, the Ile3 analog, 10, displays poor delta re- 
ceptor affinity (reduced 196-fold), while mu binding is 
only slightly reduced. While the results obtained with 
analogs 8-10 are in accord with previous reports sug- 
gesting a requirement for a residue 3/4 aromatic side 
chain (Phe or substitute) for delta but not mu binding, 
the binding data for 7, the Cha3 analog, are quite dif- 
ferent. For this peptide, a fivefold enhancement in af- 
finity at the mu receptor and an unanticipated retention 
of delta activity (affinity reduced only 2.7-fold relative 
to JOM- 13) are exhibited. This implies that aromaticity 
of the third residue per se is not a requirement for bind- 
ing of this series to the delta receptor, provided that the 
side chain is sufficiently lipophilic and reaches into the 
binding pocket. Apparently, the Val, Leu, and Ile side 
chains do not fit one or both of these criteria (or pro- 
vide some other unfavorable interaction, e.g. due per- 
haps to steric effects resulting from 8-substitution in the 
cases of Ile and Val), resulting in fairly inactive com- 
pounds. The side chain cyclohexyl functionality of 7 
most likely takes on a chair conformation, and thus in 
shape approximates a flat aromatic moiety, able to ex- 
tend into the binding pocket. The potent delta binding 
affinity of 7 suggests that either the long accepted hy- 
pothesis that an aromatic side chain (Phe or appropri- 
ate substitute) is required for delta binding is incorrect 
or that the tetrapeptide residue 3 and pentapeptide res- 
idue 4 side chains interact differently with the delta 
receptor, perhaps binding to different subsites. An ex- 
planation similar to this latter possibility has been pro- 
posed for mu ligand-receptor intcractions to explain 
discrepancies in mu binding affinities of tetrapeptides 
and pentapeptide opioids (9); however, as we have pre- 
viously reported (20), no correspondingly convincing 
evidence yet exists for delta receptor interactions. Re- 
cent evidence, in fact, suggests that the hypothesis that 
an internal aromatic residue is required for delta recep- 
tor binding is no longer tenable. We have reported that 
Cha4 substitution in a series of pentapeptide enkepha- 
lines related to DPDPE results in only a fourfold de- 
crease in delta binding affinity (21), in excellent agree- 
ment with the observations reported here for analog 7. 
In summary, the results presented here suggest dif- 
ferences in the topology of the mu and delta receptor 
subsites responsible for binding the residue 3 (in 
dermorphin/deltorphin-like opioids) or residue 4 (in en- 
kephalin analogs) side chain, with the delta receptor 
subsite consisting of a deeper hydrophobic pocket. The 
high delta receptor affinity of the Cha3 analog, 7, dem- 
onstrates that an aromatic residue, perse, is not re- 
quired for intcraction with this subsite of the delta re- 
ceptor as long as a relatively flat, lipophilic side chain 
is available for this interaction. Finally, the data pre- 
sented here are consistent with our working model that 
posits interaction with the same delta receptor binding 
loci for both tetrapeptide and pentapeptide opioids. 
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